This bill declares that the constitutional right to life applies to all human beings from the moment of conception, including fertilization. It states that Congress intends to implement this right under its powers in Article I and the 14th Amendment. The bill explicitly clarifies it does not require prosecuting women for pregnancy outcomes, ban in vitro fertilization, or restrict birth control methods. It defines "human person" to include individuals at all life stages starting at conception.
This bill denies federal funds to states or localities (sanctuary jurisdictions) that restrict sharing immigration status information or refuse to comply with federal detainer requests under specific circumstances. It specifically blocks funding intended for services like food, shelter, healthcare, legal aid, or transportation for undocumented immigrants. The funding cutoff begins 60 days after enactment or the next fiscal year start. An exception applies if a jurisdiction cooperates when an undocumented immigrant is a crime victim or witness.
The CARGO Act of 2025 prohibits the National Institutes of Health (NIH) from funding any research involving live animals conducted outside the United States. It directly affects foreign organizations and researchers who previously received NIH grants for animal research abroad, including projects funded under the $2.2 billion in grants from 2011-2021. The key provision amends the Public Health Service Act to ban NIH support for such overseas research, requiring all animal research funded by the NIH to occur within the U.S. (including territories and the District of Columbia). This change aims to address concerns about inadequate oversight of animal welfare in foreign labs where self-reported data may be inaccurate.
This bill prohibits federal funding under Title X (which supports family planning services) for clinics or organizations that perform or fund abortions, except in cases of rape, incest, or when a physician certifies a life-threatening condition. It requires grantees to certify compliance annually and mandates detailed annual reports to Congress on exceptions, including abortion counts by circumstance. The law directly affects Title X-funded providers who currently offer abortion services, potentially forcing them to stop providing abortions or lose federal funding. Key mechanisms include the certification requirement, exception criteria, and the new reporting obligations for the Secretary of Health and Human Services.
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
HR 3492, the Protect Children’s Innocence Act, makes it a federal crime to perform genital or bodily mutilation or chemical castration on minors under 18, except for specific medical reasons. The bill broadly defines prohibited procedures to include gender transition-related surgeries (like hysterectomies or mastectomies) and medical treatments such as puberty blockers or cross-sex hormones administered to minors. It criminalizes these acts when they occur across state lines, involve payments, or use interstate commerce, while explicitly banning religious tradition as a defense. Exceptions include medically necessary procedures for health emergencies, childbirth, or conditions certified by a physician.
HR 1195, the Protect Medicaid Act, prohibits federal Medicaid funds from covering administrative costs related to health benefits provided to unauthorized immigrants who lack lawful immigration status and are ineligible for Medicaid. This directly affects states that currently provide such benefits, requiring them to separate these administrative costs from general Medicaid program expenses. The bill adds a new provision to the Social Security Act clarifying that federal funds cannot be used for these specific administrative costs, while allowing funds for systems designed to enforce this rule. It also mandates an Inspector General report detailing how states separate costs, ensure compliance, finance these programs (e.g., through provider taxes), and the impact on drug pricing for this population.
HR 1463 prohibits the use of federal funds to implement, administer, or enforce a specific FDA rule about medical devices known as "laboratory developed tests" (LDTs), published in the Federal Register on May 6, 2024 (89 Fed. Reg. 37286). The bill directly affects the Food and Drug Administration (FDA), preventing it from using taxpayer money to carry out this regulation. Its key mechanism is a straightforward funding ban on the specified rule and any substantially similar future rule. This is a procedural restriction focused solely on blocking financial support for the FDA's LDT regulatory approach.
HR 679 nullifies specific changes the Food and Drug Administration (FDA) made in January 2023 to the safety rules (REMS) for the abortion pill mifepristone. The bill prohibits the FDA from implementing any future safety rules for mifepristone that are substantially similar to the nullified changes. This directly affects the FDA's regulatory authority over mifepristone, which could impact how healthcare providers prescribe the medication and how patients access it. The bill focuses solely on reversing the FDA's 2023 modifications without altering the drug's broader approval status.
HR 682, the Heartbeat Protection Act of 2025, prohibits physicians from performing abortions without first checking for a detectable fetal heartbeat according to standard medical practice and informing the patient of the results. It directly affects physicians and clinics performing abortions, requiring them to document heartbeat checks and comply with strict exceptions for life-threatening conditions, rape (with 48-hour documentation of counseling/treatment), or incest involving minors (with proof of prior report to authorities). Violations could result in fines or up to five years in prison, though the bill explicitly states it does not create or recognize a right to abortion. The law adds detailed documentation requirements for exceptions and mandates retention of medical records per federal health privacy rules.
